2414418-56-5
Chemical Structure
ZNL-02-096
- CAS No.: 2414418-56-5
- Formula:C43H47N11O6
- Molecular Weight:813.90
InChIKey: RQSGSAQIAJNYBW-UHFFFAOYSA-N
SMILES: C=CCN1C(C2=C(N1C3=NC(C(C)(O)C)=CC=C3)N=C(NC4=CC=C(N5CCN(CC5)CCCNC(C=CC=C6C(N7C8CCC(N(C8=O)C)=O)=O)=C6C7=O)C=C4)N=C2)=O
Biological Activity: ZNL-02-096 is a selective Wee1 PROTAC degrader. ZNL-02-096 binds to CRBN and Wee1 to form a ternary complex, inducing CRBN- and proteasome-dependent ubiquitination and proteasomal degradation of Wee1. ZNL-02-096 inhibits recombinant PLK1 with an IC50 of 102 nM, but does not induce its degradation in cells. ZNL-02-096 induces G2/M phase arrest, Apoptosis, transient integrated stress response, upregulation of ATF4, and phosphorylation of GCN2. ZNL-02-096 reduces Tyr15 phosphorylation of CDK1. ZNL-02-096 can be used in research related to ovarian cancer, acute lymphoblastic leukemia, triple-negative breast cancer, multiple myeloma, and pancreatic ductal adenocarcinoma[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ZNL-02-096 | ZNL-02-096 is a selective Wee1 PROTAC degrader. ZNL-02-096 binds to CRBN and Wee1 to form a ternary complex, inducing CRBN- and proteasome-dependent ubiquitination and proteasomal degradation of Wee1. ZNL-02-096 inhibits recombinant PLK1 with an IC50 of 102 nM, but does not induce its degradation in cells. ZNL-02-096 induces G2/M phase arrest, Apoptosis, transient integrated stress response, upregulation of ATF4, and phosphorylation of GCN2. ZNL-02-096 reduces Tyr15 phosphorylation of CDK1. ZNL-02-096 can be used in research related to ovarian cancer, acute lymphoblastic leukemia, triple-negative breast cancer, multiple myeloma, and pancreatic ductal adenocarcinoma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Li Z, et al. Development and Characterization of a Wee1 Kinase Degrader. Cell chemical biology. 2020 Jan 16;27(1):57-65.e9. [Content Brief]
- [2]. Wilson JCJ, et al. WEE1 inhibitors synergise with mRNA translation defects via activation of the kinase GCN2. Nature communications. 2025 Oct 09;16(1):8983. [Content Brief]
- [3]. Liu J, et al. Cell cycle on the crossroad of tumorigenesis and cancer therapy. Trends in cell biology. 2022 Jan;32(1):30-44. [Content Brief]
- [4]. Tjeerdsma RB, et al. WEE1 inhibitors trigger GCN2-mediated activation of the integrated stress response. Nature communications. 2025 Nov 24;16(1):11598. [Content Brief]
